PT  - JOURNAL ARTICLE
AU  - Boucau, Julie
AU  - Uddin, Rockib
AU  - Marino, Caitlin
AU  - Regan, James
AU  - Flynn, James P.
AU  - Choudhary, Manish C.
AU  - Chen, Geoffrey
AU  - Stuckwisch, Ashley M.
AU  - Mathews, Josh
AU  - Liew, May Y.
AU  - Singh, Arshdeep
AU  - Reynolds, Zahra
AU  - Iyer, Surabhi L.
AU  - Chamberlin, Grace C.
AU  - Vyas, Tammy D.
AU  - Vyas, Jatin M.
AU  - Turbett, Sarah E.
AU  - Li, Jonathan Z.
AU  - Lemieux, Jacob E.
AU  - Barczak, Amy K.
AU  - Siedner, Mark J.
TI  - Virologic characterization of symptom rebound following nirmatrelvir-ritonavir treatment for COVID-19
AID  - 10.1101/2022.05.24.22275326
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.24.22275326
4099  - http://medrxiv.org/content/early/2022/05/26/2022.05.24.22275326.short
4100  - http://medrxiv.org/content/early/2022/05/26/2022.05.24.22275326.full
AB  - We enrolled seven individuals with recurrent symptoms following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected at enrollment and for a median of 17 days after initial diagnosis. Three of seven had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Massachusetts Consortium for Pathogen Readiness (grants to Drs. Li, Lemieux, Siedner, and Barczak) and the Massachusetts General Hospital Department of Medicine (grant to Dr. Vyas). The BSL3 laboratory where viral culture work was performed is supported by the Harvard CFAR (P30 AI060354)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study procedures were approved by the human subjects review committee at Mass General Brigham and all participants gave informed consent to participate.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors